New cell therapy trial aims to tame eye inflammation
Disease control
Not yet recruiting
This early-stage study tests a one-time cell therapy called TRX103 for people with active non-infectious uveitis, a condition causing inflammation inside the eye. Up to 18 adults aged 18 to 70 will receive the treatment by IV and be monitored for a year. The main goal is to check…
Phase: PHASE1 • Sponsor: Quan Dong Nguyen • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC